Moderna, Inc. — Director's Dealing 2021

Apr 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2021-04-26

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-26	Common Stock	M	5000	$12.21	Acquired	5000	Direct
2021-04-26	Common Stock	S	580	$169.87	Disposed	4420	Direct
2021-04-26	Common Stock	S	439	$171.05	Disposed	3981	Direct
2021-04-26	Common Stock	S	1	$171.65	Disposed	3980	Direct
2021-04-26	Common Stock	S	200	$173.03	Disposed	3780	Direct
2021-04-26	Common Stock	S	400	$175.03	Disposed	3380	Direct
2021-04-26	Common Stock	S	551	$175.97	Disposed	2829	Direct
2021-04-26	Common Stock	S	900	$177.41	Disposed	1929	Direct
2021-04-26	Common Stock	S	1829	$178.51	Disposed	100	Direct
2021-04-26	Common Stock	S	100	$179.37	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-26	Stock Option (Right to Buy)	$12.21	M	5000	Disposed	2027-10-03	Common Stock (5000)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $169.46 to $170.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $170.61 to $171.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $172.66 to $173.39. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $174.54 to $175.40. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $175.70 to $176.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $176.92 to $177.92. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $178.06 to $178.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F9: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).